HALO

Halozyme Therapeutics, Inc. News Headlines

$7.57
*  
0.02
 negative 
0.26%
Get HALO Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Healthcare Stocks Declining Again; Halozyme Giving Back Early Gains Linked to Citigroup 'Buy' Rating
4/15/2014 1:23:32 PM - MT Newswires

Sector Update: Healthcare
4/15/2014 1:15:49 PM - MT Newswires

Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View
4/15/2014 10:27:19 AM - Benzinga

Markets Falling? Get Your Defense Ready
4/14/2014 2:47:00 PM - Investopedia

Halozyme Study Under Clinical Hold - Analyst Blog
4/10/2014 5:40:01 PM - Zacks.com

ANGO Sees Growth Ahead, DelMar On Track, HALO Loses Shine, VNDA In Launch Mode
4/10/2014 12:05:00 AM - RTT News

Halozyme Therapeutics Says FDA Places Clinical Hold On Pancreatic Cancer Trial
4/9/2014 9:49:00 AM - RTT News

Sector Update: Healthcare
4/9/2014 8:42:44 AM - MT Newswires

Sector Update: Health-Care Shares Higher Pre-Market; Intuitive Surgical Up 9% on Q1 Guidance
4/9/2014 8:41:42 AM - MT Newswires

Pre-Market Most Active for Apr 9, 2014 : NOK, FB, SIRI, AA, VZ, QQQ, SNY, BAC, GM, HALO, VOD, FCEL
4/9/2014 8:39:58 AM - NASDAQ.com News

Halozyme Falls on Phase II Study Halt - Analyst Blog
4/8/2014 12:10:01 PM - Zacks.com

What Is The Significance Of Thromboembolic Events For The Future Of Halozyme Therapeutics' PEGPH20?
4/7/2014 5:27:00 PM - Seeking Alpha

Friday's ETF Movers: GDXJ, XBI
4/4/2014 4:06:29 PM - BNK Invest

Mid-Afternoon Market Update: Markets Drop, Lead Lower by NASDAQ Momentum Names
4/4/2014 3:47:36 PM - Benzinga

Mid-Day Market Update: NASDAQ Tumbles 1.8%; SYNNEX Shares Gain After Upbeat Results
4/4/2014 12:55:12 PM - Benzinga

Halozyme Shares Plummet as Concerns Halt Trial
4/4/2014 10:19:00 AM - Fox Business

Mid-Morning Market Update: Markets Mixed; CarMax Results Miss Estimates
4/4/2014 10:14:52 AM - Benzinga

US Stocks Poised For Higher Close This Week; Mylan Reportedly Eyes Swedish Rival
4/4/2014 9:10:21 AM - MT Newswires

Stock Futures Edge Higher Even as Payroll Growth Slows, Jobless Rate Flat at 6.7%
4/4/2014 8:50:31 AM - MT Newswires

Pre-Market Most Active for Apr 4, 2014 : MU, BAC, QQQ, SEAS, HALO, WMC, FB, VOD, MYL, ALU, APC, BBL
4/4/2014 8:39:58 AM - NASDAQ.com News

Halozyme Temporarily Halts Enrollment And Dosing In Pancreatic Cancer Trial
4/4/2014 8:32:00 AM - RTT News

EC Approves Roche/Halozyme's MabThera SC - Analyst Blog
3/31/2014 11:30:01 AM - Zacks.com

Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss
3/31/2014 10:35:05 AM - Benzinga

Halozyme Says Consistent 1 Trial Of Hylenex Recombinant Met Primary Endpoint
3/31/2014 8:21:00 AM - RTT News

Halozyme: European Approval Of Roche's MabThera SC For Non-Hodgkin Lymphoma
3/28/2014 1:05:00 PM - RTT News